Dr Michael Dennis

Dr Michael Dennis

Haematology 03542754


  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Haemato-oncology


  • Face-to-face consultations
  • Home chemotherapy

About me

Mike Dennis is a Clinical Haematologist who is an established national expert in myeloid disease.

His expertise is in the management of acute myeloid leukaemia (AML), myelodysplasia (MDS), chronic myeloid leukaemia (CML), other associated myeloproliferative disorders (Myelofibrosis, CMML, ET, PRV) and bone marrow failure syndromes (including aplastic anaemia). This includes diagnosis and therapy (including stem cell transplantation)

He is a committee member of the NCRN working groups for AML and myelodysplasia, where his research roles include Chief investigator (Li1) and Co-chief investigator (AML 19) of the UK's premier front line AML studies.

His research focus is about getting access for patients to the most effective emerging agents. This is through clinical trial development of optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance and oversight.

He was appointed as a Consultant Haematologist at The Christie, Manchester in 2004. He qualified in Medicine from the University of Dundee, completed his physician’s training in Liverpool before undertaking his first Haematology post in Australia. He then completed his Haematology training, including a MD, from the University of Liverpool.

Areas of interest

• Leukaemias (AML and CML)
• Myelodysplastic syndrome (MDS)
• Myeloproliferative disorders (Myelofibrosis, ET, PRV, CMML)
• Aplastic aneamia
• Bone marrow transplantation

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0004

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

    The Christie Clinic (5-50)

  • AD832

    isavuconazole (Cresemba) 100mg capsules - (1-5)

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.